Antiproliferative agent-83
Antiproliferative agent-83 is an orally active STAT3 inhibitor (Kd = 5.63 μM) with antiproliferative activity against Huh-7 cells (IC50 = 1.30 μM). Antiproliferative agent-83 inhibits dual phosphorylation of STAT3 at tyrosine and serine residues, blocking nuclear translocation and downstream transcriptional activation. Antiproliferative agent-83 induces apoptosis, ROS accumulation, and mitochondrial depolarization. Antiproliferative agent-83 suppresses tumor growth in a hepatocellular carcinoma xenograft mouse model. Antiproliferative agent-83 can be used for research on hepatocellular carcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C32H30N4O5S
- 分子量:582.67
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Caspase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
STAT3 5.63 μM (Kd) |
Caspase 3 |
Bax |
Bcl-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | IC50 |
1.30 μM
|
Antiproliferative activity against human Huh-7 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
Antiproliferative activity against human Huh-7 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
|
42673832 |
| HepG2 | IC50 |
0.45 μM
|
Antiproliferative activity against human HepG2 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
Antiproliferative activity against human HepG2 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
|
42673832 |
| HCT-116 | IC50 |
1.50 μM
|
Antiproliferative activity against human HCT116 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
Antiproliferative activity against human HCT116 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
|
42673832 |
| MCF7 | IC50 |
0.93 μM
|
Antiproliferative activity against human MCF-7 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
Antiproliferative activity against human MCF-7 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
|
42673832 |
| MDA-MB-231 | IC50 |
3.39 μM
|
Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
|
42673832 |
| HK-2 | IC50 |
2.01 μM
|
Antiproliferative activity against human HK-2 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
Antiproliferative activity against human HK-2 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
|
42673832 |
| AML12 | IC50 |
4.51 μM
|
Antiproliferative activity against mouse AML12 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
Antiproliferative activity against mouse AML12 cells assessed as viability reduction after 48 hrs incubation by MTT assay.
|
42673832 |
体外実験
Antiproliferative agent-83 (compound 18) exhibits potent antiproliferative activity in Huh-7, HepG2, HCT116, MCF-7, MDA-MB-231, HK-2, and AML12 cells, with an IC50 of 1.30 μM against Huh-7[1].
Antiproliferative agent-83 (0.5-2 μM; 48 h, followed by 10-14 days of culture) inhibits colony formation in Huh-7 cells[1].
Antiproliferative agent-83 (2-4 μM; 24-72 h) reduces wound healing in Huh-7 cells[1].
Antiproliferative agent-83 (0.3125-10 μM; 60 s) directly binds STAT3 in SPR with a KD of 5.63 μM[1].
Antiproliferative agent-83 (0.5-2 μM; 24 h) selectively inhibits dual phosphorylation of STAT3 at Tyr705 and Ser727 in Huh-7 and HepG2 cells, without affecting total STAT3 or STAT1/STAT5 phosphorylation[1].
Antiproliferative agent-83 (2 μM; 24 h; heating at 40-60 °C for 3 min) binds to STAT3 in Huh-7 cells, producing thermal stabilization over the 40-60 °C range[1].
Antiproliferative agent-83 (1 μM; 6 h) blocks IL-6-induced nuclear translocation of p-STAT3 (Tyr705) in Huh-7 cells[1].
Antiproliferative agent-83 (4 μM; 24 h; alone at 2 μM or in combination with 5 mM NAC (HY-B0215); 24 h) induces apoptosis in Huh-7 cells, and this apoptosis can be reversed by NAC[1].
Antiproliferative agent-83 (2 μM; 24 h) upregulates cleaved caspase-3 and Bax and downregulates Bcl-2 in Huh-7 cells[1].
Antiproliferative agent-83 (0.5-4 μM; 24 h) inhibits ATP production in Huh-7 cells with an IC50 of 1.55 μM[1].
Antiproliferative agent-83 (0.25-1 μM; 24 h; 0.5 μM combined with 5 mM NAC; 24 h) increases ROS in Huh-7 cells, and this increase can be reversed by NAC[1].
Antiproliferative agent-83 (0.5-2 μM; 24 h) induces mitochondrial depolarization[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Huh-7 cells
-
Concentration:0.5, 1, 2 μM
-
Incubation Time:48 h; 10-14 days culture
-
Result:Suppressed colony formation in a dose-dependent manner.
-
Cell Line:Huh-7 cells
-
Concentration:2, 4 μM
-
Incubation Time:0, 24, 48, 72 h
-
Result:Reduced wound healing in Huh-7 cells.
-
Cell Line:Huh-7 cells
-
Concentration:1, 2, 4 μM
2 μM alone or with 5 mM NAC (HY-B0215) -
Incubation Time:24 h
-
Result:Triggered a prominent increase in apoptotic Huh-7 cells, with apoptotic cells reaching 53.6% at 4 μM.
Produced an apoptotic rate of 32.1% in the NAC rescue experiment, which decreased to 10.23% upon co-incubation with 5 mM NAC; control was 6.05%.
-
Cell Line:Huh-7 and HepG2 cells
-
Concentration:0.5, 1, 2 μM (Huh-7 and HepG2)
2 μM alone or with 5 mM NAC (Huh-7 NAC rescue) -
Incubation Time:24 h
-
Result:Exerted prominent inhibitory effects on dual STAT3 phosphorylation at Tyr705 and Ser727 in both Huh‑7 and HepG2 cells, while producing no obvious effect on total STAT3 expression.
Showed negligible impacts on STAT1, p-STAT1 (Tyr701), STAT5, and p-STAT5 (Tyr694).
NAC did not restore compound 18-mediated downregulation of p-STAT3 (Ser727).
-
Cell Line:Huh-7 cells
-
Concentration:1 μM
IL-6 50 ng/mL -
Incubation Time:6 h (preincubation)
30 min (IL-6 stimulation) -
Result:Displayed intense nuclear fluorescence of p-STAT3 (Tyr705); this nuclear translocation was markedly suppressed in cells.
-
Cell Line:Huh-7 cells
-
Concentration:0.5, 1, 2 μM
-
Incubation Time:24 h
-
Result:Upregulated cleaved caspase-3 and Bax and downregulates Bcl-2 in Huh-7 cells.
Parmacokinetics
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c-nude (male, 5-6 weeks, 18-20 g, injected with Huh-7 cells (3 × 106 cells/mouse))[1]
-
Dosage:5 mg/kg; 7.5 mg/kg
-
Administration:intraperitoneal injection; every 3 days; for 13 days
-
Result:In the Huh-7 xenograft nude mouse model, Antiproliferative agent-83 produced tumor inhibition rate (TIR) values of 54.43% at 5 mg/kg and 55.08% at 7.5 mg/kg.
Only a minimal difference in TIR was observed between the two doses of Antiproliferative agent-83.
化学情報
-
分子量 582.67
-
分子式 C32H30N4O5S
-
SMILES
O=C(C)C1=NC(C(N2CCC3(CCN(C(C4=CC5=C(C=CC=C5)S4(=O)=O)=O)CC3)CC2)=O)=CC6=C1NC7=C6C=CC=C7
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Antiproliferative agent-83
- Antiproliferative agent83
- Antiproliferative agent 83
- STAT
- Caspase
- Bcl-2 Family
- Reactive Oxygen Species (ROS)
- Apoptosis
- STAT3
- apoptosis
- breast cancer
- colorectal cancer
- hepatocellular carcinoma
- mitochondrial depolarization
- nuclear translocation
- reactive oxygen species
- transcriptional activation
- xenograft
- Inhibitor
- inhibitor
- inhibit